A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
Study Details
Study Description
Brief Summary
Human papillomavirus (HPV) infection has become one of the most important health problems faced by women all over the world. A large number of studies have shown that women's cervical, vaginal and perianal precancerous lesions, related cancers, condyloma acuminatum and other sexually transmitted diseases (STD) are closely related to HPV infection. Among them, the persistent infection of high-risk human papillomavirus (HR-HPV) is closely related to the occurrence of invasive cervical cancer. Previous studies have shown that there are significant differences in the effects of multiple HPV infection and persistent infection of different types (such as type-16, -18, -39 and -52) on different levels of cervical lesions, and there is a certain correlation between HPV load in the process of persistent infection and the degree of cervical lesions. In addition, other studies have shown that HPV-16 viral load has certain clinical significance in predicting Cin2 / CIN3 high-grade cervical lesions, and HPV viral load level is significantly different in cervical low-grade squamous intraepithelial lesion (LSIL) and cervical high-grade squamous intraepithelial lesion (HSIL). The above biological changes such as HPV infection type, quantity and proportion can promote the occurrence and development of cervical precancerous lesions and related cancers to varying degrees. It can be seen that the study of the relationship between HPV viral load and cervical lesions is of great significance for clinical disease development prediction and cervical cancer screening.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Based on previous studies and clinical practice, this study carried out a multi center cohort study in China. In this study, ten research including Fujian Maternity and Child Health Hospital, Mindong Hospital of Ningde City, Zhangzhou affiliated Hospital of Fujian Medical University, Quanzhou First Hospital Afflicated to Fujian Medical University, The First Hospital of Putian City, Ningde Municipal Hospital of Ningde Normal University, Shenzhen Maternity and child Healthcare Hospital and Maternity and child Hospital of Hubei Province were included, each of which included 400 individuals, with a total of 4000 women with high-grade squamous intraepithelial lesion were enrolled. For the first time, the investigators will collect 2 samples of cervical exfoliated cells and 4 samples of vaginal fornix swabs from participants, then at the 6th, 12th and 24th months after the first sampling, the participants need to return to the hospital, collected 2 samples of cervical exfoliated cells and 4 samples of vaginal fornix swabs again in order to observe and record the development of the disease. During this process, if abnormal cervical lesions are found, the participants will be biopsied under colposcopy according to relevant guidelines. Samples from cervix would be sent for PCR-sequencing, HPV tests and Thinprep cytologic test (TCT). And samples from vaginal fornix would be sent for sequencing and bioinformatic analysis. A prospective cohort study was conducted to explore the correlation between the characteristics, progression and prognosis of female genital tract lesions and HPV infection type, load and vaginal microenvironment.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Women with high-grade squamous intraepithelial lesion (HSIL) in cervix In the enrollment, women whose cervical histopathological results have been diagnosed as high-grade squamous intraepithelial lesion (HSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months. |
Other: Follow-up
Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
|
Outcome Measures
Primary Outcome Measures
- Cervical histopathology testing at baseline [Baseline]
Cervical histopathology was performed at baseline for all participants.
- Cervical histopathology testing at 6-month follow-up [6-month follow-up]
Cervical histopathology was performed at 6-month follow-up for cervical HPV infection or cytology abnormalities women.
- Cervical histopathology testing at 12-month follow-up [12-month follow-up]
Cervical histopathology was performed at 12-month follow-up for cervical HPV infection or cytology abnormalities women.
- Cervical histopathology testing at 24-month follow-up [24-month follow-up]
Cervical histopathology was performed at 24-month follow-up for cervical HPV infection or cytology abnormalities women.
- Human Papillomavirus (HPV) viral load test at baseline [Baseline]
Human Papillomavirus (HPV) viral load test was performed at baseline for all participants.
- Human Papillomavirus (HPV) viral load test at 6-month follow-up [6-month follow-up]
All participants were tested for HPV viral load at the time of 6-month follow-up.
- Human Papillomavirus (HPV) viral load test at 12-month follow-up [12-month follow-up]
All participants were tested for HPV viral load at the time of 12-month follow-up.
- Human Papillomavirus (HPV) viral load test at 24-month follow-up [24-month follow-up]
All participants were tested for HPV viral load at the time of 24-month follow-up.
- Cervical cytology testing at baseline [Baseline]
All participants were tested for cervical cytology at the time of baseline.
- Cervical cytology testing at 6-month follow-up [6-month follow-up]
All participants were tested for Cervical cytology testing at the time of 6-month follow-up.
- Cervical cytology testing at 12-month follow-up [12-month follow-up]
All participants were tested for Cervical cytology testing at the time of 12-month follow-up.
- Cervical cytology testing at 24-month follow-up [24-month follow-up]
All participants were tested for Cervical cytology testing at the time of 24-month follow-up.
- 16SrRNA sequencing of the vaginal secretions at baseline [Baseline]
All participants underwent vaginal secretion sequencing at baseline.
- 16SrRNA sequencing the vaginal secretions at 6-month follow-up [6-month follow-up]
All participants underwent vaginal secretion sequencing at the time of 6-month follow-up.
- 16SrRNA sequencing of the vaginal secretions at 12-month follow-up [12-month follow-up]
All participants underwent vaginal secretion sequencing at the time of 12-month follow-up.
- 16SrRNA sequencing of the vaginal secretions at 24-month follow-up [24-month follow-up]
All participants underwent vaginal secretion sequencing at the time of 24-month follow-up.
Secondary Outcome Measures
- Human Papillomavirus (HPV) genotyping tests at baseline [Baseline]
All participants underwent Human Papillomavirus (HPV) genotyping tests at baseline.
- Human Papillomavirus (HPV) genotyping tests at 6-month follow-up [6-month follow-up]
All participants underwent Human Papillomavirus (HPV) genotyping tests at the time of 6-month follow-up.
- Human Papillomavirus (HPV) genotyping tests at 12-month follow-up [12-month follow-up]
All participants underwent Human Papillomavirus (HPV) genotyping tests at the time of 12-month follow-up.
- Human Papillomavirus (HPV) genotyping tests at 24-month follow-up [24-month follow-up]
All participants underwent Human Papillomavirus (HPV) genotyping tests at the time of 24-month follow-up.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Women aged 20 and over.
-
The result of cervical histopathology in the last 3 months was high-grade squamous intraepithelial lesion (HSIL).
-
Non pregnant people with sexual history.
-
Asexual life, no vaginal medication or flushing before 72 hours of sampling.
Exclusion Criteria:
-
Within 8 weeks after pregnancy or postpartum.
-
Patients with history of genital tract tumor.
-
History of HPV vaccination.
-
Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical.
-
In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma.
-
Use antibiotics or vaginal microecological improvement products in recent 1 month.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Fujian Maternity and Child Health Hospital | Fuzhou | Fujian | China | 350001 |
| 2 | Mindong Hospital of Ningde City | Ningde | Fujian | China | 352000 |
| 3 | Ningde Municipal Hospital of Ningde Normal University | Ningde | Fujian | China | 352100 |
| 4 | The First Hospital of Putian City | Putian | Fujian | China | 351100 |
| 5 | Quanzhou First Hospital Afflicated to Fujian Medical University | Quanzhou | Fujian | China | 362000 |
| 6 | Zhangzhou affiliated Hospital of Fujian Medical University | Zhangzhou | Fujian | China | 363000 |
| 7 | Longyan First Hospital | Longyan | China | ||
| 8 | Shenzhen Maternity and child Healthcare Hospital | Shenzhen | China | ||
| 9 | Maternity and child Hospital of Hubei Province | Wuhan | China | ||
| 10 | Xiamen Maternity and Child Health Hospital | Xiamen | China |
Sponsors and Collaborators
- Fujian Maternity and Child Health Hospital
Investigators
- Study Chair: Pengming Sun, PhD, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PVLHCF